Health-related quality of life after interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with stage III ovarian cancer

ConclusionThe addition of HIPEC to interval CRS does not negatively impact HRQoL in patients with stage III ovarian cancer who are treated with interval CRS. These HRQoL results, together with the improvement in RFS and OS, support the viability of HIPEC as an important treatment option in this patient population.ClinicalTrials.gov numberNCT00426257.EudraCT number2006-003466-34.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research